Maxim lowered the firm’s price target on Sensus Healthcare (SRTS) to $10 from $14 and keeps a Buy rating on the shares. The firm is updating its estimates to reflect the company’s Q1 results and its expectations as well as citing its shift from a pure capital sales model to include its Fair Deal Agreement model, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare: Strong Q1 Performance and Strategic Shifts Justify Buy Rating
- Sensus Healthcare’s Earnings Call: Mixed Outlook with Growth Potential
- Sensus Healthcare: Overcoming Challenges with Strategic Growth and Clinical Success
- Sensus Healthcare Reports Q1 2025 Financial Results
- Sensus Healthcare reports Q1 EPS (16c), consensus 2c